Wechalekar Mihir D, Lester Susan, Proudman Susanna M, Cleland Leslie G, Whittle Samuel L, Rischmueller Maureen, Hill Catherine L
Queen Elizabeth Hospital and Flinders University, Adelaide, South Australia, Australia.
Arthritis Rheum. 2012 May;64(5):1316-22. doi: 10.1002/art.33506.
To determine whether application of criteria for remission in rheumatoid arthritis (RA) may result in underestimation of foot joint involvement among patients in a clinic setting.
RA patients (n = 123) were assessed at baseline and 6 months after commencement of a response-driven combination disease-modifying antirheumatic drug (DMARD) protocol. Remission was assessed using disease activity measures (the 28-joint Disease Activity Score using the erythrocyte sedimentation rate [DAS28-ESR], Simplified Disease Activity Index [SDAI], and Clinical Disease Activity Index [CDAI]) as well as Boolean-based criteria for remission (the 1981 American College of Rheumatology [ACR] preliminary criteria and the 2011 ACR/European League Against Rheumatism [EULAR] provisional criteria). The prevalence of foot synovitis and the mean swollen/tender foot joint count in RA patients meeting any of these remission criteria were estimated by hurdle (mixed distribution) regression.
In patients who received 6 months of combination DMARD treatment, application of the 1981 ACR criteria and the newly proposed 2011 ACR/EULAR criteria, each utilizing full joint counts (which includes assessment of the feet), classified the least number of patients as being in remission (8-10%), and evidence of foot synovitis was minimal among these patients. In contrast, ongoing foot synovitis was present in a substantial proportion of patients (>20%) meeting the 28-joint count criteria for remission, including the DAS28-ESR, SDAI, CDAI, and 2011 ACR/EULAR criteria (clinical practice setting or clinical trials). Furthermore, applying the 2011 ACR/EULAR composite remission criterion of a SDAI score ≤3.3 to define remission did not adequately capture the resolution of foot synovitis (i.e., residual foot involvement was still detected in a substantial proportion of patients classified as being in remission by this definition).
Although the DAS28-ESR, CDAI, and SDAI have been validated for assessment of remission in RA, this study shows that the performance of these 3 disease activity measures, which do not provide a direct assessment of the foot, in detecting foot synovitis is poor, in contrast to that of the 1981 ACR and 2011 ACR/EULAR remission criteria utilizing full joint counts. Thus, patients may be at risk of ongoing damage if treatment decisions are made solely on the basis of criteria that omit foot joint assessment.
确定类风湿关节炎(RA)缓解标准的应用是否会导致门诊患者足部关节受累情况被低估。
对123例RA患者在基线期以及开始采用反应驱动的联合改善病情抗风湿药(DMARD)方案治疗6个月后进行评估。使用疾病活动度指标(采用红细胞沉降率的28关节疾病活动评分 [DAS28-ESR]、简化疾病活动指数 [SDAI] 和临床疾病活动指数 [CDAI])以及基于布尔值的缓解标准(1981年美国风湿病学会 [ACR] 初步标准和2011年ACR/欧洲抗风湿病联盟 [EULAR] 临时标准)评估缓解情况。通过门槛(混合分布)回归估计符合这些缓解标准中任何一项的RA患者足部滑膜炎的患病率以及足部肿胀/压痛关节的平均计数。
在接受6个月联合DMARD治疗的患者中,应用1981年ACR标准和新提出的2011年ACR/EULAR标准(均采用全部关节计数,其中包括足部评估)将最少比例的患者分类为处于缓解状态(8 - 10%),并且这些患者中足部滑膜炎的证据极少。相比之下,在符合28关节计数缓解标准(包括DAS28-ESR、SDAI、CDAI和2011年ACR/EULAR标准,无论是临床实践环境还是临床试验)的患者中,相当大比例(>20%)存在持续性足部滑膜炎。此外,应用SDAI评分≤3.3的2011年ACR/EULAR综合缓解标准来定义缓解并不能充分反映足部滑膜炎的消退情况(即,在根据该定义被分类为缓解的患者中,仍有相当大比例检测到残留的足部受累情况)。
尽管DAS28-ESR、CDAI和SDAI已被验证可用于评估RA的缓解情况,但本研究表明,这3种疾病活动度指标在检测足部滑膜炎方面表现不佳,因为它们没有对足部进行直接评估,这与采用全部关节计数的1981年ACR和2011年ACR/EULAR缓解标准相反。因此,如果仅根据省略足部关节评估的标准做出治疗决策,患者可能面临持续损伤的风险。